203Pb-VMT-α-NET Scintigraphy of a Patient With Neuroendocrine Tumor

In an end-stage midgut neuroendocrine tumor patient with carcinoid heart disease, right ventricular dysfunction, mildly reduced renal function, and refractory to 6 cycles of Lu-177-HA-DOTATATE therapy, planar, and 22 hours SPECT/CT images were acquired after injection of 224 MBq of Pb-203-VMT-alpha-NET to assess the feasibility of performing Pb-212-VMT-alpha-NET therapy. A comparison of the 1.5 and 22 hours SPECT/CT images with Ga-68-HA-DOTATATE PET/CT showed high uptake of Pb-203-VMT-alpha-NET in liver metastases matching with the results of the PET/CT investigation.

Automated summary

In a patient with end-stage midgut neuroendocrine tumor, various imaging techniques were used to assess the feasibility of Pb-212-VMT-alpha-NET therapy. The results of planar, 22 hours SPECT/CT, and Ga-68-HA-DOTATATE PET/CT images showed high uptake of Pb-203-VMT-alpha-NET in liver metastases.